National Health Insurance Research Database (NHIRD)
Overview
The National Health Insurance Research Database (NHIRD) in Taiwan is a population-level data source, covering approximately 23 million individuals, accounting for 99.9% of the Taiwanese population. The NHIRD contains demographic information and medical claims data for a wide range of healthcare services, including records from outpatient visits, emergency department visits, hospitalizations, procedures, and prescriptions. It helps construct longitudinal histories, making it feasible for cohort study designs. It can be linked to various other national health-related databases, including Cause of Death data, the Taiwan Cancer Registry Database, the Taiwan Biobank, Birth Certificates Application (BCA) database, and Registry of Catastrophic Illness Patients, etc. To ensure patient privacy, personal identification numbers are encrypted and replaced with unique, anonymous identifiers. These anonymous identifiers are then used as linkage keys to connect data across multiple databases. For more detailed information about the NHIRD, please refer to the OCEAN platform. The integration of multiple databases enhances the NHIRD’s utility as a comprehensive real-world resource for diverse longitudinal studies and provides extensive insights into public health trends across Taiwan.
Selected publications:
Li BM, Yang AS, Cheng MC, et al. Risk of suicide in patients with atrial fibrillation receiving different oral anticoagulants: a nationwide analysis using target trial emulation framework. BMC Med. 2024;22(1):451. Published 2024 Oct 11. doi:10.1186/s12916-024-03645-z
Huang WC, Yang AS, Tsai DH, et al. Association between recently raised anticholinergic burden and risk of acute cardiovascular events: nationwide case-case-time-control study. BMJ. 2023;382:e076045. Published 2023 Sep 27. doi:10.1136/bmj-2023-076045
Huang HK, Liu PP, Lin SM, et al. Diabetes-Related Complications and Mortality in Patients With Atrial Fibrillation Receiving Different Oral Anticoagulants : A Nationwide Analysis. Ann Intern Med. 2022;175(4):490-498. doi:10.7326/M21-3498
Lee WA, Shao SC, Liao TC, et al. Comparative Risk of Arterial Thromboembolic Events Between Aflibercept and Ranibizumab in Patients with Maculopathy: A Population-Based Retrospective Cohort Study. BioDrugs. 2021;35(5):579-588. doi:10.1007/s40259-021-00497-4